Hypoxia and Medicine

Intestinal Ischemia News

ACG Releases Evidence-Based Systematic Review on Management of Irritable Bowel SyndromeThursday, December 18, 2008 @ 7:00AM New Graded Recommendations Clarify the Clinical Options for Physicians and Patients

Sanofi-aventis NewsThursday, July 31, 2008 @ 7:00AM Sanofi-aventis announces solid growth in the second quarter.

Landmark ATHENA Study Findings With Multaq(R)(droned.Thursday, May 15, 2008 @ 12:14PMParis (ots/PRNewswire) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that findings from the landmark ATHENA study showed that Multaq(R) (dronedarone), a potential therapy for the treatment of patients with atrial fibrillation or atrial flutter, decreased the risk of cardiovascular hospitalisations or death from any cause by a statistically significant 24% (p=0.00000002), meeting ...

Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or ...Thursday, May 15, 2008 @ 12:12PMParis (ots/PRNewswire) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that findings from the landmark ATHENA study showed that Multaq(R) ...

Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or ...Thursday, May 15, 2008 @ 12:07PMParis (ots/PRNewswire) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that findings from the landmark ATHENA study showed that Multaq(R) (dronedarone), a potential therapy for the treatment of patients with atrial fibrillation or ...